TheraRadar

Enanta

Pre-Approval PRO BETA
43
Total Trials
0
Phase 3
11
Phase 2
1
Recruiting
194
Score

Pipeline by Phase

Phase 3
Phase 2
11
Phase 1
32

Therapeutic Focus

RSV Infection NASH - Nonalcoholic Steatohepatitis Respiratory Syncytial Virus (RSV) COVID-19 Non-Alcoholic Steatohepatitis

Clinical Trials (43)

NCT07482657 Phase 2 NOT YET RECRUITING

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Started: 7/1/2026

NCT06170242 Phase 2 COMPLETED

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Started: 11/20/2023

NCT04816721 Phase 2 COMPLETED

A Study to Evaluate EDP 938 Regimens in Children With RSV

Started: 4/26/2022

NCT05568706 Phase 2 COMPLETED

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Started: 11/29/2022

NCT04633187 Phase 2 TERMINATED

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

Started: 7/7/2021

NCT05616728 Phase 2 COMPLETED

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

Started: 11/10/2022

NCT04196101 Phase 2 COMPLETED

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

Started: 1/22/2020

NCT04378010 Phase 2 TERMINATED

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Started: 1/27/2020

NCT03691623 Phase 2 COMPLETED

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

Started: 10/15/2018

NCT03421431 Phase 2 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Started: 4/25/2018

NCT03394924 Phase 2 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Started: 12/27/2017

NCT07540910 Phase 1 RECRUITING

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Started: 4/1/2026

NCT06601192 Phase 1 COMPLETED

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Started: 7/15/2024

NCT06847464 Phase 1 COMPLETED

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Started: 1/27/2025

NCT06917508 Phase 1 COMPLETED

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Started: 3/13/2025

NCT05587478 Phase 1 COMPLETED

A Study of EDP-323 in Healthy Subjects

Started: 9/29/2022

NCT05594602 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Started: 10/6/2022

NCT05594615 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Started: 10/6/2022

NCT05246878 Phase 1 COMPLETED

A Study of EDP-235 in Healthy Subjects

Started: 1/28/2022

NCT04927793 Phase 1 COMPLETED

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Started: 5/28/2021

NCT04971512 Phase 1 TERMINATED

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Started: 8/2/2021

NCT04470388 Phase 1 COMPLETED

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Started: 9/9/2020

NCT04008004 Phase 1 COMPLETED

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Started: 6/26/2019

NCT04559126 Phase 1 COMPLETED

A Study of EDP-297 in Healthy Subjects

Started: 9/8/2020

NCT04498741 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Started: 7/8/2020

NCT04783753 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

Started: 11/5/2020

NCT04871724 Phase 1 COMPLETED

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Started: 3/12/2021

NCT03783897 Phase 1 COMPLETED

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

Started: 11/27/2018

NCT03755778 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Started: 11/29/2018

NCT03750383 Phase 1 COMPLETED

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

Started: 11/2/2018

NCT03610945 Phase 1 COMPLETED

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

Started: 7/19/2018

NCT03748628 Phase 1 COMPLETED

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

Started: 10/5/2018

NCT03384823 Phase 1 COMPLETED

A Study of EDP-938 in Healthy Subjects

Started: 12/7/2017

NCT03207425 Phase 1 COMPLETED

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Started: 6/14/2017

NCT03213145 Phase 1 COMPLETED

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

Started: 7/11/2017

NCT02918929 Phase 1 COMPLETED

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Started: 9/1/2016

NCT03187496 Phase 1 COMPLETED

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

Started: 5/11/2017

NCT02652377 Phase 1 COMPLETED

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Started: 1/10/2016

NCT01856426 Phase 1 COMPLETED

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Started: 6/1/2013

NCT02255968 Phase 1 TERMINATED

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

Started: 8/1/2014

NCT02173574 Phase 1 COMPLETED

Two-way Interaction Between Alisporivir and EDP239

Started: 8/1/2014

NCT01999725 Phase 1 COMPLETED

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

Started: 1/1/2014

NCT00990145 Phase 1 COMPLETED

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

Started: 11/1/2008

Drug Candidates

zelicapavir Placebo EDP-323 Dose Regimen 1 EDP-323 Dose Regimen 2 EDP-938 zelicapavir (therapeutic dose) zelicapavir (supratherapeutic dose) moxifloxacin EDP-323 Itraconazole
Activity Status: Active
Last Trial Started: 7/1/2026
Last Trial Ended: 6/23/2025
Trials (12 months): 2
Completed Trials: 37
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.